Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings ; volume:22 ; number:1 ; day:3 ; month:12 ; year:2022 ; pages:1-11 ; date:12.2022
BMC pulmonary medicine ; 22, Heft 1 (3.12.2022), 1-11, 12.2022
- Creator
-
Aksamit, Timothy
Wu, Jasmanda
Hassan, Mariam
Achter, Emily
Chatterjee, Anjan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-022-02257-8
- URN
-
urn:nbn:de:101:1-2023021421304201670006
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aksamit, Timothy
- Wu, Jasmanda
- Hassan, Mariam
- Achter, Emily
- Chatterjee, Anjan
- SpringerLink (Online service)
Other Objects (12)
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
Inhalation
Scale-up of liposome manufacturing : combining high pressure liposome extrusion with drying technologies
Scale-up of liposome manufacturing : combining high pressure liposome extrusion with drying technologies
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
Inhalation
Scale-up of liposome manufacturing : combining high pressure liposome extrusion with drying technologies
Scale-up of liposome manufacturing : combining high pressure liposome extrusion with drying technologies
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension
Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
Inhalation
Scale-up of liposome manufacturing : combining high pressure liposome extrusion with drying technologies